Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001767 · ClinicalTrials.gov registry record · Phase 2
Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease
A Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01001767 is a Phase 2 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 35 participants.
The verdict
NCT01001767, a Phase 2 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Several studies have shown that there is an increased risk of heart disease in people with HIV. In this study the investigators are looking at the effect of Lovaza (Omega-3 fatty acid) on improving endothelial function and decreasing inflammation which may contribute to this increased risk. The investigators will also be doing studies to analyze coagulation and inflammation markers.
Interventions
- DRUG Placebo
- DRUG Lovaza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001767
The ClinicalTrials.gov registry entry for NCT01001767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01001767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001767 about?
NCT01001767 is a clinical study titled "Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease". Several studies have shown that there is an increased risk of heart disease in people with HIV. In this study the investigators are looking at the effect of Lovaza (Omega-3 fatty acid) on improving endothelial function and decreasing inflammation which may contribute to this increased risk. The inve...
What is the current status of trial NCT01001767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2009-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01001767?
The interventions under investigation include: Placebo (DRUG), Lovaza (DRUG).
Who is sponsoring clinical trial NCT01001767?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.